{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T21:10:23Z","timestamp":1743282623601,"version":"3.40.3"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>In recent years, there has been active research investigating whether traditional Chinese medicines, such as Tongxinluo, generate any cardiovascular benefits. Tongxinluo, composed of powders and extracts from multiple plant, insect, and animal products, was approved in 1996 in China for the treatment of angina pectoris and ischemic stroke, but the evidence regarding its benefits remained sparse. Recently, a large randomized controlled trial investigated the use of Tongxinluo in acute ST-segment elevation myocardial infarction and found a significant difference in the 30-day major adverse cardiac and cerebrovascular events (MACCEs) in the Tongxinluo group compared with the control group. The individual components of 30-day MACCEs, including cardiac death, were also significantly lower in the Tongxinluo group. After 1 year, the Tongxinluo group still had a significantly lower rate of MACCEs. In search of further benefits, another recent large randomized controlled trial investigated the use of Tongxinluo in acute ischemic stroke, and the results showed a significantly higher proportion of favorable functional outcomes at day 90 in the Tongxinluo group compared with the control group. The Tongxinluo group also had a significantly higher proportion of patients with a National Institutes of Health Stroke Scale score reaching 0 or 1 or with a reduction of more than 4 points. Despite these studies demonstrating Tongxinluo\u2019s cardiovascular benefits, its role in the treatment of these diseases as an adjunct to guideline-directed therapies is still not well-defined, and it remains to be seen whether these trials will result in significant changes in Tongxinluo\u2019s clinical utility.<\/jats:p>","DOI":"10.1097\/crd.0000000000000901","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:36:10Z","timestamp":1743280570000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tongxinluo, a Chinese Medicine Compound With Cardiovascular Benefits"],"prefix":"10.1097","author":[{"given":"Mohammed","family":"Kallash","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, School of Medicine, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, School of Medicine, Valhalla, NY"},{"name":"Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"R1-20250326","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2023.19524","article-title":"Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial.","volume":"330","author":"Yang","year":"2023","journal-title":"JAMA"},{"key":"R2-20250326","doi-asserted-by":"crossref","first-page":"e002790","DOI":"10.1161\/CIRCOUTCOMES.116.002790","article-title":"Cardiac and noncardiac causes of long-term mortality in ST-segment-elevation acute myocardial infarction patients who underwent primary percutaneous coronary intervention.","volume":"10","author":"Yamashita","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"Supplement 2","key":"R3-20250326","first-page":"S6","article-title":"Global epidemiology of stroke and access to acute ischemic stroke interventions.","volume":"97","author":"Saini","year":"2021","journal-title":"Neurology"},{"key":"R4-20250326","doi-asserted-by":"crossref","first-page":"H1967","DOI":"10.1152\/ajpheart.00944.2009","article-title":"The challenge of traditional Chinese medicines for allopathic practitioners.","volume":"297","author":"Karalliedde","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R5-20250326","first-page":"1529","article-title":"Pretreatment with Tongxinluo protects porcine myocardium from ischaemia\/reperfusion injury through a nitric oxide related mechanism.","volume":"122","author":"Cheng","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"R6-20250326","doi-asserted-by":"crossref","first-page":"H1255","DOI":"10.1152\/ajpheart.00459.2010","article-title":"Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway.","volume":"299","author":"Li","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R7-20250326","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3760\/cma.j.issn.0366-6999.20130224","article-title":"Protein kinase a-mediated cardioprotection of Tongxinluo relates to the inhibition of myocardial inflammation, apoptosis, and edema in reperfused swine hearts.","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"R8-20250326","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s12010-021-03680-z","article-title":"Peoniflorin preconditioning protects against myocardial ischemia\/reperfusion injury through inhibiting myocardial apoptosis: RISK pathway involved.","volume":"194","author":"Ma","year":"2022","journal-title":"Appl Biochem Biotechnol"},{"key":"R9-20250326","first-page":"157","article-title":"Ginsenoside Rg1 inhibits myocardial ischaemia and reperfusion injury via HIF-1 \u03b1-ERK signalling pathways in a diabetic rat model.","volume":"74","author":"Yuan","year":"2019","journal-title":"Die Pharmazie"},{"key":"R10-20250326","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fphys.2018.00078","article-title":"Ginsenoside Rg1 ameliorates rat myocardial ischemia-reperfusion injury by modulating energy metabolism pathways.","volume":"9","author":"Li","year":"2018","journal-title":"Front Physiol"},{"key":"R11-20250326","doi-asserted-by":"crossref","first-page":"109913","DOI":"10.1016\/j.biopha.2020.109913","article-title":"Ginsenoside Rb1 attenuates cardiomyocyte apoptosis induced by myocardial ischemia reperfusion injury through mTOR signal pathway.","volume":"125","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R12-20250326","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FJC.0000000000000104","article-title":"Induction of autophagy by Tongxinluo through the MEK\/ERK pathway protects human cardiac microvascular endothelial cells from hypoxia\/reoxygenation injury.","volume":"64","author":"Cui","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R13-20250326","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3389\/fphar.2017.00775","article-title":"Inhibition of miR-128-3p by tongxinluo protects human cardiomyocytes from ischemia\/reperfusion injury via upregulation of p70s6k1\/p-p70s6k1.","volume":"8","author":"Chen","year":"2017","journal-title":"Front Pharmacol"},{"key":"R14-20250326","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.7150\/thno.43163","article-title":"Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia\/Reperfusion injury.","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"R15-20250326","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1113\/EP086192","article-title":"Tongxinluo exerts protective effects via anti-apoptotic and pro-autophagic mechanisms by activating AMPK pathway in infarcted rat hearts.","volume":"102","author":"Li","year":"2017","journal-title":"Exp Physiol"},{"key":"R16-20250326","doi-asserted-by":"crossref","first-page":"116011","DOI":"10.1016\/j.jep.2022.116011","article-title":"Tongxinluo attenuates atherosclerosis by inhibiting ROS\/NLRP3\/caspase-1-mediated endothelial cell pyroptosis.","volume":"304","author":"Jiang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"R17-20250326","first-page":"2858","article-title":"No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial).","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"R18-20250326","doi-asserted-by":"crossref","first-page":"e2433463","DOI":"10.1001\/jamanetworkopen.2024.33463","article-title":"Tongxinluo and functional outcomes among patients with acute ischemic stroke.","volume":"7","author":"Dong","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R19-20250326","first-page":"CD004474","article-title":"Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris.","volume":"2006","author":"Wu","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R20-20250326","doi-asserted-by":"crossref","first-page":"742978","DOI":"10.3389\/fphar.2021.742978","article-title":"Efficacy and safety of tongxinluo capsule as adjunctive treatment for unstable angina pectoris: a systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Li","journal-title":"Front Pharmacol"},{"key":"R21-20250326","doi-asserted-by":"crossref","first-page":"e35405","DOI":"10.1097\/MD.0000000000035405","article-title":"Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: a meta-analysis and systematic review.","volume":"102","author":"Feng","year":"2023","journal-title":"Medicine (Baltimore)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:37:02Z","timestamp":1743280622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000901","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}